Researchers from the Medical University of Vienna in Austria have discovered a new factor in the development and progression of the most common type of liver cancer, hepatocellular carcinoma (HCC), the university has said.
The team from the Institute of Cancer Research found the AXL receptor tyrosine kinase both supported cancer-advancing processes and inhibited anti-cancer mechanisms, Xinhua reported citing the university statement issued Thursday.
Team leader Wolfgang Mikulits said he was surprised the function of the AXL receptor now hardly had to be studied as the receptor was found to be activated in more than 50 percent of HCC patients.
The team was able to demonstrate that the presence and activation of the receptor led to a switch of signalling pathways that allowed for the migration and metastasis of liver cancer cells, as well as disabled the anti-cancer activity of the protein TGF beta.
An analysis of tumour samples from patients confirmed the experimental data.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
